These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2728 related items for PubMed ID: 15842167

  • 1. Protein promiscuity: drug resistance and native functions--HIV-1 case.
    Fernández A, Tawfik DS, Berkhout B, Sanders R, Kloczkowski A, Sen T, Jernigan B.
    J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
    [Abstract] [Full Text] [Related]

  • 2. Adaptive inhibitors of the HIV-1 protease.
    Ohtaka H, Freire E.
    Prog Biophys Mol Biol; 2005 Jun; 88(2):193-208. PubMed ID: 15572155
    [Abstract] [Full Text] [Related]

  • 3. Comparative studies on inhibitors of HIV protease: a target for drug design.
    Jayaraman S, Shah K.
    In Silico Biol; 2008 Jun; 8(5-6):427-47. PubMed ID: 19374129
    [Abstract] [Full Text] [Related]

  • 4. Structure-based phenotyping predicts HIV-1 protease inhibitor resistance.
    Shenderovich MD, Kagan RM, Heseltine PN, Ramnarayan K.
    Protein Sci; 2003 Aug; 12(8):1706-18. PubMed ID: 12876320
    [Abstract] [Full Text] [Related]

  • 5. Domain flexibility in retroviral proteases: structural implications for drug resistant mutations.
    Rose RB, Craik CS, Stroud RM.
    Biochemistry; 1998 Feb 24; 37(8):2607-21. PubMed ID: 9485411
    [Abstract] [Full Text] [Related]

  • 6. A molecular dynamics study comparing a wild-type with a multiple drug resistant HIV protease: differences in flap and aspartate 25 cavity dimensions.
    Seibold SA, Cukier RI.
    Proteins; 2007 Nov 15; 69(3):551-65. PubMed ID: 17623840
    [Abstract] [Full Text] [Related]

  • 7. Multidrug resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations.
    Ohtaka H, Schön A, Freire E.
    Biochemistry; 2003 Nov 25; 42(46):13659-66. PubMed ID: 14622012
    [Abstract] [Full Text] [Related]

  • 8. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
    Muzammil S, Ross P, Freire E.
    Biochemistry; 2003 Jan 28; 42(3):631-8. PubMed ID: 12534275
    [Abstract] [Full Text] [Related]

  • 9. Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Das K, Lewi PJ, Hughes SH, Arnold E.
    Prog Biophys Mol Biol; 2005 Jun 28; 88(2):209-31. PubMed ID: 15572156
    [Abstract] [Full Text] [Related]

  • 10. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K.
    Verh K Acad Geneeskd Belg; 2001 Jun 28; 63(5):447-73. PubMed ID: 11813503
    [Abstract] [Full Text] [Related]

  • 11. Structural insights into the mechanisms of drug resistance in HIV-1 protease NL4-3.
    Heaslet H, Kutilek V, Morris GM, Lin YC, Elder JH, Torbett BE, Stout CD.
    J Mol Biol; 2006 Mar 03; 356(4):967-81. PubMed ID: 16403521
    [Abstract] [Full Text] [Related]

  • 12. A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease.
    Vega S, Kang LW, Velazquez-Campoy A, Kiso Y, Amzel LM, Freire E.
    Proteins; 2004 May 15; 55(3):594-602. PubMed ID: 15103623
    [Abstract] [Full Text] [Related]

  • 13. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL.
    APMIS Suppl; 2003 May 15; (114):1-37. PubMed ID: 14626050
    [Abstract] [Full Text] [Related]

  • 14. Molecular dynamics studies on HIV-1 protease drug resistance and folding pathways.
    Cecconi F, Micheletti C, Carloni P, Maritan A.
    Proteins; 2001 Jun 01; 43(4):365-72. PubMed ID: 11340653
    [Abstract] [Full Text] [Related]

  • 15. New anti-HIV agents and targets.
    De Clercq E.
    Med Res Rev; 2002 Nov 01; 22(6):531-65. PubMed ID: 12369088
    [Abstract] [Full Text] [Related]

  • 16. HIV-1 protease molecular dynamics of a wild-type and of the V82F/I84V mutant: possible contributions to drug resistance and a potential new target site for drugs.
    Perryman AL, Lin JH, McCammon JA.
    Protein Sci; 2004 Apr 01; 13(4):1108-23. PubMed ID: 15044738
    [Abstract] [Full Text] [Related]

  • 17. Novel drug resistance mutations in HIV: recognition and clinical relevance.
    Perno CF, Svicher V, Ceccherini-Silberstein F.
    AIDS Rev; 2006 Apr 01; 8(4):179-90. PubMed ID: 17219733
    [Abstract] [Full Text] [Related]

  • 18. Prediction of HIV-1 protease inhibitor resistance using a protein-inhibitor flexible docking approach.
    Jenwitheesuk E, Samudrala R.
    Antivir Ther; 2005 Apr 01; 10(1):157-66. PubMed ID: 15751773
    [Abstract] [Full Text] [Related]

  • 19. How Mutations Can Resist Drug Binding yet Keep HIV-1 Protease Functional.
    Appadurai R, Senapati S.
    Biochemistry; 2017 Jun 13; 56(23):2907-2920. PubMed ID: 28505418
    [Abstract] [Full Text] [Related]

  • 20. Role of conformational fluctuations in the enzymatic reaction of HIV-1 protease.
    Piana S, Carloni P, Parrinello M.
    J Mol Biol; 2002 May 31; 319(2):567-83. PubMed ID: 12051929
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 137.